Press release 23.07.26
Through this collaboration, Uniphar will leverage its expertise in cross-border access, patient access support, market access, and reimbursement navigation to help eligible patients navigate pathways to authorized treatment centres in the United States that are authorized to administer TECELRA®.
For eligible patients with metastatic synovial sarcoma, an aggressive disease with significant unmet medical need and limited treatment options, this partnership is intended to facilitate a clear pathway to timely access TECELRA® through authorized U.S. treatment centers.
The collaboration also reflects the growing importance of specialized cross-border access models for advanced cell and gene therapies. Uniphar’s regional expertise and established network across MENA position the company to support biopharmaceutical partners seeking to make highly specialized therapies available to patients with rare diseases.
“This new partnership reinforces Uniphar’s commitment to helping patients access highly specialized medicines, particularly where treatment options are limited. By combining our regional expertise across MENA with US WorldMeds’ innovation in advanced cell therapy, we can support a clearer pathway for eligible patients and their clinicians to access TECELRA® through authorized treatment centers in the US.” Explains Brian O’Shaughnessy, Chief Commercial Officer at Uniphar.
“TECELRA® represents an important advance for eligible patients with metastatic synovial sarcoma,” said Breck Jones, Sr., CEO at US WorldMeds. “Through our collaboration with Uniphar, we hope to help remove logistical and access barriers that can affect patients seeking treatment outside their home country and support access to care through authorized treatment centers in the United States.”
ENDS
About Uniphar:
Headquartered in Dublin, Ireland, Uniphar is an international diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions — Uniphar Pharma, Uniphar Medtech, and Uniphar Supply Chain & Retail. The Group is active in Europe, North America, APAC and MENA. Operating across 180 countries with a global team of 3,500+, Uniphar bridges manufacturers, healthcare providers, and patients — accelerating access to innovative therapies, improving patient outcomes, and delivering value across the healthcare ecosystem.
Uniphar Pharma integrates Development, Clinical, Access, Medical, Commercial, Distribution and Global Sourcing to support the full product lifecycle – from early-stage research through to commercialization and beyond. Uniphar’s unified platform spans regulatory strategy, clinical trial support, medical affairs, market access, patient engagement, commercial services, distribution and supply chain. For more information, please visit www.uniphar.com
About US WorldMeds:
US WorldMeds is a U.S.-based biopharmaceutical company focused on rare and specialty treatments. Our portfolio includes approved therapies for rare diseases and bleeding disorders, including IWILFIN®, REVONTO®, and TECELRA®.
About Synovial Sarcoma:
There are more than 50 different types of soft tissue sarcomas which can arise in fat, muscle, nerves, fibrous tissues, blood vessels, or deep skin tissues.1 Synovial sarcoma accounts for approximately 5 to 10% of all soft tissue sarcomas.1,2 Approximately one-third of patients with synovial sarcoma are diagnosed under the age of 30.2 The five-year survival rate for people with metastatic disease is approximately 20% and recurrence is common in advanced disease.1,3
About TECELRA®:
TECELRA® (afamitresgene autoleucel) is a genetically modified autologous T cell immunotherapy indicated for adult and pediatric patients 12 years of age and older with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A02:01P, -A02:02P, -A02:03P, or -A02:06P positive, and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices. TECELRA is made from a patient’s own white blood cells that are genetically modified to recognize and attack cancer cells. A healthcare provider will perform tests to see if TECELRA is right for each patient.
IMPORTANT SAFETY INFORMATION:
Important Warning: You will likely be in a hospital before and after getting TECELRA. TECELRA may cause side effects that can be severe or life-threatening. Call your healthcare provider or get emergency help right away if you get any of the following: fever (100.4°F/38°C or higher); chills/shivering; difficulty breathing; fast or irregular heartbeat; low blood pressure; fatigue; severe nausea, vomiting, or diarrhea; severe headache; or new skin rash. Tell all your healthcare providers that you were treated with TECELRA.
After getting TECELRA, you will be monitored daily at the healthcare facility for at least 7 days after the infusion. You should plan to stay close to a healthcare facility for at least 2 weeks. Do not drive, operate heavy machinery, or do other activities that could be dangerous for at least 2 weeks after you get TECELRA. Your healthcare provider will do blood tests to follow your progress. It is important that you have your blood tested. If you miss a scheduled appointment for your collection of blood, call your healthcare provider as soon as possible to reschedule.
Before you receive TECELRA, tell your healthcare provider about all the medicines and supplements you take and your medical conditions, including: seizure, stroke, confusion, or memory loss; heart, liver, or kidney problems; low blood pressure; lung or breathing problems; recent or active infection; past infections that can be reactivated following treatment with TECELRA; low blood counts; pregnancy, you think you may be pregnant, or plan to become pregnant; breastfeeding; or taking a blood thinner.
The most common side effects of TECELRA include nausea, fatigue, infection, fever (100.4°F/38°C or higher), constipation, vomiting, headache, diarrhea, fast heart rate, cough, increased aspartate aminotransferase, increased alanine aminotransferase, decreased lymphocyte count, decreased white blood cell count, decreased neutrophil count, decreased red blood cell count, and decreased platelet count.
You are encouraged to report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to US WorldMeds at 1-855-246-9232.
Please see full Prescribing Information, including Boxed Warning and Medication Guide.
References:
1 “What is a Soft Tissue Sarcoma?” American Cancer Society. https://www.cancer.org/cancer/types/soft-tissue-sarcoma/about/soft-tissue-sarcoma.html. Accessed May 15, 2026.
2 “Soft Tissue Sarcoma.” Cleveland Clinic. https://my.clevelandclinic.org/health/diseases/21732-soft-tissue-sarcoma. Accessed May 15, 2026.
3 Jami SA, Mobarak SA, Jiandang S, et al. Clinical and strategic outcomes of metastatic synovial sarcoma on limb. Int J Health Sci(Qassim). 2020;14:38–43.
*Per Kaplan-Meier method